Evaluating the Idylla ThyroidPrint Assay for Indeterminate Thyroid Nodules
Official title: Idylla™ ThyroidPrint® RUO Assay Beta-Trial Study
Run by Royal Cornwall Hospitals Trust · NCT06849284 · Data updated 2026-11-12
This study is testing if the Idylla ThyroidPrint Assay can help doctors better understand indeterminate thyroid nodules by comparing its results to those from surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Royal Cornwall Hospitals Trust Academic / other |
| Locations | 1 site (Truro, Cornwall) |
| Status | Recruiting |
| Started | December 16, 2024 |
| Main results expected | June 30, 2025 |
| Study ends | June 30, 2025 |
| Registry record updated | June 4, 2025 |
| Trial ID | NCT06849284 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with thyroid nodules that are 1.0 cm or larger and have been classified as indeterminate based on cytology.
✕Probably not a fit
Patients with thyroid nodules that do not meet the inclusion criteria or those with evidence of malignant cervical adenopathy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the performance of the Idylla™ ThyroidPrint® Assay in predicting the nature of indeterminate thyroid nodules using clinical samples. It is a multicenter, prospective study that matches the assay results to the gold standard of surgical pathology. The primary focus is to calculate the sensitivity, specificity, and predictive values of the assay, while also evaluating its failure rate and the nature of any false results.
Why it matters
Potential benefit: If successful, this study could improve the diagnostic accuracy for patients with indeterminate thyroid nodules, potentially leading to better treatment decisions.
How similar studies have gone: Other studies have explored similar diagnostic assays for thyroid nodules, but the specific performance of the Idylla ThyroidPrint Assay in this context is being evaluated for the first time.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Thyroid nodule ≥1.0 cm * With indeterminate cytology * Surgery due to be performed Exclusion Criteria: * Specimens which fail to meet the inclusion criteria. * FNA fixed in formalin or transferred in alcohol-based collection buffers which is not according to the protocol instructions. * RNA extracts. * Patients with ultrasound evidence of malignant cervical adenopathy
Where it's running
-
Royal Cornwall Hospital
Truro, Cornwall, United Kingdom Recruiting
Study contacts
- Study coordinator: Verity Teague Research Sponsorship Facilitator
- Email: rcht.sponsor@nhs.net
- Phone: 0044 1872256429
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer
In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.
-
Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer
This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
-
WeChat-supported neck exercises after thyroidectomy
A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.
-
Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors
This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.
-
AI chatbot to guide thyroid cancer patients through perioperative education
A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.